The Headlines – `Indian pharma resilient to potential US tariffs’

India Ratings and Research (Ind-Ra) anticipates minimal credit profile impact on Indian pharma companies from potential US tariffs on pharmaceutical imports. While the US accounts for a significant portion of revenue for these companies, its contribution has been declining.

The Headlines – Latest Business News Today: Stock Markets, Financial News, India Business & World Business News – Read More